Total Synthesis of Neuroprotective Dictyoquinazol A, B, and C

  title={Total Synthesis of Neuroprotective Dictyoquinazol A, B, and C},
  author={Chang Ho Oh and Chung Hyun Song},
  journal={Synthetic Communications},
  pages={3311 - 3317}
  • C. Oh, C. Song
  • Published 1 September 2007
  • Chemistry
  • Synthetic Communications
Abstract A new protective compound, dictyoquinazol A, was synthesized starting from 5‐methoxy‐2‐nitrobenzoic acid in six‐steps in 36% overall yield. Two derivatives B and C, isolated from the mushroom Dictyophora indusiata, were also synthesized from Dictyoquinazole A. 
Synthesis and neuroprotective activity of dictyoquinazol A and analogues.
A flexible and efficient synthesis of the neuroprotective alkaloid, dictyoquinazol A, is reported, and a new molecular scaffold is established that holds promise for a novel pharmaceutical treatment for stroke. Expand
Syntheses of indolo[1,2-a]quinazolinone derivatives via palladium catalyzed intramolecular C–H amidation
The synthesis of indolo[1,2-a]quinazolinone starting from 2-iodobenzamide and indole derivatives is reported. In this two-step procedure, indole is N-arylated with 2-iodobenzamide derivatives viaExpand
Synthesis of 3-substituted and 2,3-disubstituted quinazolinones via Cu-catalyzed aryl amidation.
Under these conditions other amides that were tested only provided simple coupling products, which can be converted into 2,3-disubstituted quinazolinones via HMDS/ZnCl(2) mediated condensative cyclization. Expand
Synthesis of N-Heteropolycyclic Compounds Including Quinazolinone Skeleton Using Friedel–Crafts Alkylation
Abstract A simple method to synthesize N-heteropolycyclic quinazolinones was developed including Knoevenagel condensation of quinazolines and aldehydes and Friedel–Craft alkylation as key steps.Expand
The Chemistry, Pharmacology and Therapeutic Potential of the Edible Mushroom Dictyophora indusiata (Vent ex. Pers.) Fischer (Synn. Phallus indusiatus)
Of the bioactive compounds, the chemistry of the polysaccharides as major bioactive components primarily the β-glucan with side branches of β-(1→6)-glucosyl units are discussed, while small molecular weight compounds include terpenoids and alkaloids. Expand
Edible and Medicinal Mushrooms: Emerging Brain Food for the Mitigation of Neurodegenerative Diseases.
In this review, the scientific information on edible and culinary mushrooms with regard to their antidementia/AD active compounds and/or pharmacological test results are summarized and may be regarded as functional foods for the mitigation of neurodegenerative diseases. Expand


Dictyoquinazols A, B, and C, new neuroprotective compounds from the mushroom Dictyophora indusiata.
Dictyoquinazols protected primary cultured mouse cortical neurons from glutamate- and NMDA-induced excitotoxicities in a dose-dependent manner. Expand
Neuroprotective bibenzyl glycosides of Stemona tuberosa roots.
Three new bibenzyl glycosides characterized as stilbostemin B, H, and I significantly protected human neuroblastoma SH-SY5Y cells from 6-hydroxydopamine-induced neurotoxicity. Expand
Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists.
Quinazolin-4-one derivatives of methaqualone substituted at C-2 define a new class of noncompetitive antagonists at AMPA receptors.
Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists: structure-activity relationship of the C-2 side chain tether.
New AMPA receptor antagonists, containing the methylamino tether group, have been identified from this effort, and the relative potencies of the new compounds ranged from 11 nM to greater than 10 microM. Expand
The role of excitatory amino acids and NMDA receptors in traumatic brain injury.
Brain injury induced by fluid percussion in rats caused a marked elevation in extracellular glutamate and aspartate adjacent to the trauma site, which contributes to delayed tissue damage after brain trauma. Expand
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
It was concluded that clinically manifest Parkinsonism represents the late, "decompensated", stage of a disease characterized by a progressive striatal DA deficiency; and the striatum can compensate functionally for lower degrees of DA deficiency. Expand
The role of glutamate in neurotransmission and in neurologic disease.
Pharmacologic manipulation of the glutamatergic system may have great potential for the rational treatment of a variety of neurologic diseases. Expand
AMPA receptor agonists, antagonists and modulators: their potential for clinical utility
From the understanding of neuronal circuitry and its involvement in brain function, agonists and positive allosteric modulators are predicted to improve the negative symptomatology in schizophrenia, and to improve memory, behavioural and cognition skills in dementias associated with neurodegenerative disorders or trauma. Expand